PharmaNetics
This article was originally published in The Gray Sheet
Executive Summary
Ecarin clotting time test gains humanitarian device exemption approval from FDA to monitor patients with Heparin Induced Thrombocytopenia who receive Refludan, Aventis' thrombin inhibitor drug treatment, during cardiopulmonary bypass procedures